Ignite Creation Date:
2025-12-24 @ 2:58 PM
Ignite Modification Date:
2026-03-01 @ 6:02 AM
Study NCT ID:
NCT00407459
Status:
COMPLETED
Last Update Posted:
2011-09-02
First Post:
2006-12-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Sponsor:
Armando Santoro, MD
Organization:
Study Overview
Official Title:
Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
Detailed Description:
Secondary endpoints are to evaluate:
* the objective response rate (RR) of the combination;
* the toxicity and the safety profile of the combination;
* the duration of response (RD) and time to treatment failure (TTF);
* the overall survival (OS)
* RR, TTP and OS according to baseline plasma VEGF levels (introduced with Amendment 1 dated 8/11/2007)
* the objective response rate (RR) of the combination;
* the toxicity and the safety profile of the combination;
* the duration of response (RD) and time to treatment failure (TTF);
* the overall survival (OS)
* RR, TTP and OS according to baseline plasma VEGF levels (introduced with Amendment 1 dated 8/11/2007)
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| EUDRACT 2006-004429-27 | None | None | View |